Literature DB >> 27366226

The interplay between the microbiome and the adaptive immune response in cancer development.

Edda Russo1, Antonio Taddei2, Maria Novella Ringressi2, Federica Ricci1, Amedeo Amedei3.   

Abstract

The data from different studies suggest a bacterial role in cancer genesis/progression, often modulating the local immune response. This is particularly so at the mucosal level where the bacterial presence is strong and the immune system is highly reactive. The epithelial surfaces of the body, such as the skin and mucosa, are colonized by a vast number of microorganisms, which represent the so-called normal microbiome. Normally the microbiome does not cause a proinflammatory response because the immune system has developed different strategies for the tolerance of commensal bacteria, but when these mechanisms are impaired or new pathogenic bacteria are introduced into this balanced system, the immune system reacts to the microbiome and can trigger tumor growth in the intestine. In this review, we discuss the potential role of the bacterial microbiome in carcinogenesis, focusing on the direct and indirect immune adaptive mechanisms, that the bacteria can modulate in different ways.

Entities:  

Keywords:  Th17; adaptive immune response; bacteria; colorectal cancer; microbiome

Year:  2016        PMID: 27366226      PMCID: PMC4913328          DOI: 10.1177/1756283X16635082

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  104 in total

1.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes.

Authors:  Edith M Janssen; Edward E Lemmens; Tom Wolfe; Urs Christen; Matthias G von Herrath; Stephen P Schoenberger
Journal:  Nature       Date:  2003-02-09       Impact factor: 49.962

2.  Perspective: alpha-bugs, their microbial partners, and the link to colon cancer.

Authors:  Cynthia L Sears; Drew M Pardoll
Journal:  J Infect Dis       Date:  2010-12-08       Impact factor: 5.226

3.  CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice.

Authors:  Susan E Erdman; Jane J Sohn; Varada P Rao; Prashant R Nambiar; Zhongming Ge; James G Fox; David B Schauer
Journal:  Cancer Res       Date:  2005-05-15       Impact factor: 12.701

Review 4.  Cancer and the microbiome: potential applications as new tumor biomarker.

Authors:  Khan Shahanavaj; Ignacio Gil-Bazo; Marta Castiglia; Giuseppe Bronte; Francesco Passiglia; Anna P Carreca; José Luis del Pozo; Antonio Russo; Marc Peeters; Christian Rolfo
Journal:  Expert Rev Anticancer Ther       Date:  2014-12-15       Impact factor: 4.512

5.  Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.

Authors:  Weici Zhang; Yongyan Chen; Haiming Wei; Chaogu Zheng; Rui Sun; Jian Zhang; Zhigang Tian
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

6.  Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.

Authors:  Chung-Wei Lee; Barry Rickman; Arlin B Rogers; Zhongming Ge; Timothy C Wang; James G Fox
Journal:  Cancer Res       Date:  2008-04-25       Impact factor: 12.701

7.  Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice.

Authors:  Klara Klimesova; Miloslav Kverka; Zuzana Zakostelska; Tomas Hudcovic; Tomas Hrncir; Renata Stepankova; Pavel Rossmann; Jakub Ridl; Martin Kostovcik; Jakub Mrazek; Jan Kopecny; Koichi S Kobayashi; Helena Tlaskalova-Hogenova
Journal:  Inflamm Bowel Dis       Date:  2013-05       Impact factor: 5.325

8.  The prevalence of Th17 cells in patients with gastric cancer.

Authors:  Bin Zhang; Guanghua Rong; Huafeng Wei; Meng Zhang; Jianwei Bi; Liye Ma; Xuchao Xue; Guo Wei; Xiaokang Liu; Guoen Fang
Journal:  Biochem Biophys Res Commun       Date:  2008-07-23       Impact factor: 3.575

9.  CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice.

Authors:  Susan E Erdman; Varada P Rao; Theofilos Poutahidis; Melanie M Ihrig; Zhongming Ge; Yan Feng; Michal Tomczak; Arlin B Rogers; Bruce H Horwitz; James G Fox
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

10.  Gut microbiomes of Malawian twin pairs discordant for kwashiorkor.

Authors:  Michelle I Smith; Tanya Yatsunenko; Mark J Manary; Indi Trehan; Rajhab Mkakosya; Jiye Cheng; Andrew L Kau; Stephen S Rich; Patrick Concannon; Josyf C Mychaleckyj; Jie Liu; Eric Houpt; Jia V Li; Elaine Holmes; Jeremy Nicholson; Dan Knights; Luke K Ursell; Rob Knight; Jeffrey I Gordon
Journal:  Science       Date:  2013-01-30       Impact factor: 47.728

View more
  23 in total

Review 1.  Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms.

Authors:  Tsuyoshi Hamada; Jonathan A Nowak; Danny A Milner; Mingyang Song; Shuji Ogino
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

2.  NLRC3 regulates cellular proliferation and apoptosis to attenuate the development of colorectal cancer.

Authors:  Rajendra Karki; R K Subbarao Malireddi; Qifan Zhu; Thirumala-Devi Kanneganti
Journal:  Cell Cycle       Date:  2017-06-09       Impact factor: 4.534

3.  Intestinal bacterium-derived cyp27a1 prevents colon cancer cell apoptosis.

Authors:  Yan-Chao Ji; Chang Liu; Xia Zhang; Cheng-Sen Zhang; Dong Wang; Yan Zhang
Journal:  Am J Transl Res       Date:  2016-10-15       Impact factor: 4.060

4.  Fecal microbiome in systemic sclerosis, in search for the best candidate for microbiota-targeted therapy for small intestinal bacterial overgrowth control.

Authors:  Elisa Fiorentini; Edda Russo; Amedeo Amedei; Silvia Bellando Randone
Journal:  J Scleroderma Relat Disord       Date:  2022-09-25

Review 5.  Intervention strategies for microbial therapeutics in cancer immunotherapy.

Authors:  V Gopalakrishnan; B Weiner; C B Ford; B R Sellman; S A Hammond; D J Freeman; P Dennis; J-C Soria; J R Wortman; M R Henn
Journal:  Immunooncol Technol       Date:  2020-05-20

Review 6.  Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.

Authors:  Richard Greil; Evelyn Hutterer; Tanja Nicole Hartmann; Lisa Pleyer
Journal:  Cell Commun Signal       Date:  2017-01-19       Impact factor: 5.712

7.  A cross-sectional comparative study of gut bacterial community of Indian and Finnish children.

Authors:  Shreyas V Kumbhare; Himanshu Kumar; Somak P Chowdhury; Dhiraj P Dhotre; Akihito Endo; Jaana Mättö; Arthur C Ouwehand; Samuli Rautava; Ruchi Joshi; Nitinkumar P Patil; Ravindra H Patil; Erika Isolauri; Ashish R Bavdekar; Seppo Salminen; Yogesh S Shouche
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

Review 8.  Exploring the Oral Microbiome in Rheumatic Diseases, State of Art and Future Prospective in Personalized Medicine with an AI Approach.

Authors:  Silvia Bellando-Randone; Edda Russo; Vincenzo Venerito; Marco Matucci-Cerinic; Florenzo Iannone; Sabina Tangaro; Amedeo Amedei
Journal:  J Pers Med       Date:  2021-06-30

9.  Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study.

Authors:  Edda Russo; Giovanni Bacci; Carolina Chiellini; Camilla Fagorzi; Elena Niccolai; Antonio Taddei; Federica Ricci; Maria N Ringressi; Rossella Borrelli; Filippo Melli; Manouela Miloeva; Paolo Bechi; Alessio Mengoni; Renato Fani; Amedeo Amedei
Journal:  Front Microbiol       Date:  2018-01-12       Impact factor: 5.640

Review 10.  Linking Gut Microbiota to Colorectal Cancer.

Authors:  Hans Raskov; Jakob Burcharth; Hans-Christian Pommergaard
Journal:  J Cancer       Date:  2017-09-20       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.